

1 **Title**

2 Defining the Burden of Disease of RSV in Europe: estimates of RSV-associated
3 hospitalisations in children under 5 years of age. A systematic review and modelling study.

4

5 **Authors:** Marco Del Riccio¹, Peter Spreuwenberg¹, Richard Osei-Yeboah³, Caroline K.
6 Johannesen⁴, Liliana Vazquez Fernandez⁵, Anne C. Teirlinck⁶, Xin Wang⁷, Terho Heikkinen⁸,
7 Mathieu Bangert⁹, Saverio Caini¹, Harry Campbell³, John Paget¹ on behalf of the RESCEU
8 investigators

9

10 **Affiliations:**

- 11 1. Netherlands Institute for Health Services Research (Nivel), Utrecht, The Netherlands
12 2. Department of Health Sciences, University of Florence, 50134 Florence, Italy
13 3. Centre for Global Health, Usher Institute, University of Edinburgh
14 4. Statens Serum Institut, Copenhagen, Denmark
15 5. Department of Methods Development & Analytics, Norwegian Institute of Public
16 Health, Oslo, Norway
17 6. Centre for Infectious Disease Control, National Institute for Public Health and the
18 Environment, Bilthoven, the Netherlands
19 7. School of Public Health, Nanjing Medical University, Nanjing, China
20 8. Department of Pediatrics, University of Turku and Turku University Hospital, Turku,
21 Finland
22 9. Sanofi Vaccines, Lyon, France

23

24

25 **Abstract**

26 **Background:** Respiratory syncytial virus (RSV) infections cause an estimated 22-50 million
27 episodes of acute lower respiratory infections (ALRI) every year in children younger than 5
28 years. To date, no overall estimate of RSV-associated hospitalisations in children under 5 years
29 has been published for the European Union (EU). Through statistical modelling, we estimated
30 the RSV hospitalisation burden in children under 5 years of age in EU countries and Norway,
31 by age group and country.

32 **Methods:** We collated national RSV-associated hospitalisation estimates calculated using
33 linear regression models in children under 5 years via the RESCEU project for Denmark,
34 England, Finland, Norway, the Netherlands and Scotland during 2006-2018. A systematic
35 literature review was conducted to collect additional estimates. Using the multiple imputation
36 and nearest neighbour matching extrapolation methods, we estimated RSV-associated
37 hospitalisation rates in all EU countries.

38 **Results:** Additional estimates for Spain and France were found in the literature and added to
39 the analysis. We estimated that an average of 245,244 (95%CI 224,688-265,799) hospital
40 admissions with a respiratory infection per year were associated with RSV in children under
41 the age of 5, with most cases occurring among children aged less than 1 year (75%). Infants
42 aged less than 2 months represented the most affected group (71.6 per 1,000 children; 95%CI:
43 66.6-76.6). The hospitalisation rates varied widely across countries: for example, estimated
44 rates in the 0-2 months age group ranged from 47.4 (37.5-57.3) per 1,000 in the Netherlands to
45 98.3 (88.5-108.1) per 1,000 in France.

46 **Conclusion:** To our knowledge, this is the first attempt to estimate the overall RSV
47 hospitalisation burden in children under the age of 5 years in the EU. Our findings will help
48 support decisions regarding prevention efforts, and they will also represent an important

49 benchmark to understand changes in the RSV burden following the introduction of RSV
50 immunisation programs in Europe.

51

52 **Keywords:** Respiratory Syncytial Virus; Hospitalization; Burden of disease; Respiratory
53 Hospitalization; Europe; Modelling.

54

55 **Introduction**

56 It is globally estimated that respiratory syncytial virus (RSV) is associated with about 22% of
57 all acute lower respiratory infections (ALRI) [1] and this results in approximately 101,400
58 (84,500 – 125,200) deaths per year in young children [2]. Several studies have been conducted
59 to understand the burden of RSV-associated infections, hospitalisations, and deaths in children
60 in Europe. For example, Reeves et al. explored routinely collected hospital data on RSV in
61 children aged <5 years in 7 European countries and compared these to RSV-associated
62 admission rates [3], while Demont et al. provided information on the clinical and economic
63 burden of RSV-associated hospitalisation in children aged <5 years in France between 2010
64 and 2018 [4]. Despite these efforts, no estimates for RSV-associated hospitalisations are
65 available for children in the EU as a whole.

66 RSV-associated hospitalisation estimates are important for public health purposes, as they can
67 help allocate resources, and provide important insights and inputs for prevention measures and
68 strategies. The establishment of a robust age-specific burden of disease estimates, which have
69 often been limited due to a lack of routine testing for RSV [5], has also been underlined by the
70 World Health Organization (WHO) [6].

71 In this paper, we present overall and country-specific estimates of RSV-associated respiratory
72 hospitalisations (absolute numbers and rates) by age group in children aged less than 5 years
73 in the 28 countries of the European Union (EU-28: includes the United Kingdom (UK) as it
74 was part of EU when the data were collected) and Norway. We then used these estimates to
75 calculate the proportion of RSV-associated hospitalisations among all-cause hospitalisations
76 and respiratory hospitalisations in this age group, for each country. Estimates of the hospital
77 burden of RSV are not available in many EU countries and our data will allow comparisons
78 between countries and with other regions of the world, support efforts to communicate the RSV
79 disease burden, and provide important data for decisions regarding future prevention and

80 control measures linked to various immunisation programmes (such as vaccines and/or
81 monoclonal antibodies).

82

83 **Methods**

84 *Data sources*

85 We searched for published and unpublished national estimates of RSV-associated
86 hospitalisations (defined as any admission that contained at least one respiratory infection-
87 specific ICD-10 code at any point during admission) in children under 5 years in EU countries
88 that were calculated using regression models as input data for the statistical analysis.

89

90 *RSV-associated hospitalisation estimates from the RESCEU project*

91 The data sources for Denmark, England, Finland, Norway, the Netherlands, and Scotland have
92 been described in papers that were previously published by the REspiratory Syncytial virus
93 Consortium in EUrope (RESCEU) [3]. Briefly, a retrospective study of overall respiratory
94 hospital admissions (i.e., respiratory tract infections with or without an associated pathogen),
95 RSV-related respiratory admissions, and other pathogen-respiratory admissions in children <5
96 years of age using routinely collected hospital admissions databases was conducted in these 6
97 countries of the EU/European Economic Area (EEA). Age-specific estimates of RSV-
98 associated hospitalisations in children during 2006-2018 were calculated for these countries by
99 using a linear regression approach [7], with estimates available for the following age groups:
100 0-2, 3-5, 6-11, 12-35, and 36-59 months.

101

102 *Literature review estimates to identify estimates in other countries*

103 In order to increase the geographical representativeness of this work, we searched the scientific
104 literature for additional data points in EU countries by adopting the same search strategy as a

105 previously published systematic review that aimed to estimate the global incidence, hospital
106 admission rate, and mortality due to RSV in young children based on national estimates [2].
107 The systematic review by Li et al. was broader in scope and inclusion criteria (i.e., they
108 included studies reporting incidence and in-hospital and out-of-hospital mortality, not only
109 hospitalisation rates), therefore, we considered that the included records needed to be further
110 screened and assessed for eligibility in our review.

111 The new search was conducted according to the Preferred Reporting Items for Systematic
112 Reviews and Meta-Analyses (PRISMA) statement [8]. The same search string as the systematic
113 review conducted by Li and colleagues was used [2] (see Supplementary material); MEDLINE
114 and EMBASE databases were searched from 1st January 2019 to 30th November 2021 for
115 original articles. Papers published before 2019 that had been included by Li and colleagues
116 were added to the reference list of relevant papers and further assessed for eligibility. No
117 language restrictions were applied as long as an English abstract was available to decide on
118 eligibility. To be included, a study had to report (i) national estimates of RSV-associated
119 hospitalisations in children in EU countries calculated by using regression models (in order to
120 have a homogeneous pool of estimates) (ii) details (i.e., ICD codes) on the diagnosis (i.e.,
121 bronchiolitis, lower respiratory infections, etc.), and (iii) analyse the same age bands used by
122 Johannesen and colleagues [7].

123 After removing duplicates, titles and abstracts were independently screened by two researchers
124 (MDR and ROY) and the articles that were not excluded were retrieved in full copy and
125 independently read by two authors (MDR and ROY). The papers that had been included in the
126 previous systematic review were further assessed for eligibility, and the reference list of all
127 eligible papers was checked by means of backward citation chaining for further relevant
128 references. Data extraction was organised using an internally piloted spreadsheet [2]. The
129 estimates reported by the included articles were then extracted and used as input data for the

130 statistical modelling, along with other information (data sources, details on the primary
131 diagnosis, years in which the study was conducted, etc.). The quality assessment of the included
132 studies was conducted by using a tool designed by Li et al. [2] (see Supplementary material).
133 Based on the assessment of different questions (on study testing, subjects, case definition,
134 sampling strategy, diagnostic tests, adjustment for health-care utilization) an overall score was
135 calculated.

136

137 *Statistical Analysis*

138 A two stage-modelling approach was used to estimate the respiratory hospitalisation burden of
139 RSV in children under 5 years old. This method was adapted from prior work focused on
140 influenza-associated mortality during the 2009 pandemic [9] and for seasonal influenza [10].
141 Since the period covered by the eligible studies was 2006-2018, the United Kingdom (UK) was
142 included in the EU estimates.

143 In Stage 1, we identified annual age-specific estimates of RSV-associated hospitalisations from
144 respiratory causes that were calculated using regression models. Data from the six RESCEU
145 countries, plus those which were found in the literature and matched the inclusion criteria (see
146 Results), were used as input data for Stage 2.

147 In Stage 2, we used the country estimates to extrapolate the hospitalisation burden and generate
148 plausible values for all EU countries and Norway using two different modelling approaches,
149 each involving two steps: (1) a data creation step using the matching approach or the multiple
150 imputation approach, and (2) a data analysis step where a hierarchical linear random effects
151 model is used to project the burden in all EU countries. For both approaches, the data creation
152 step relied on 10 country-specific indicators representing health conditions at a demographic,
153 geographic and population level (see Supplementary material) [9]. As two different sets of 10
154 indicators were used, the statistical modelling produced 4 sets of results (see Supplementary

155 material), each related to the combination of one set of indicators and one modelling approach.
156 An average of the four different models was calculated and this was used to calculate the
157 absolute annual number and rates of RSV-associated hospitalisations (with uncertainty
158 intervals) by country for the following age groups: 0-2, 3-5, 6-11, 12-35, and 36-59 months,
159 which are consistent with the previously published age groups used by Johannesen and
160 colleagues [7]. We also assessed the hospitalisations rate for EU28 in children aged 0-59
161 months and calculated the ratio of hospitalisations that occurred in each age group, considering
162 our estimated total number of RSV-associated hospitalisations as denominator.
163 Finally, in order to compare RSV-associated hospitalisations to total respiratory and all-cause
164 hospitalisations, the estimated absolute number of RSV-associated hospitalisations was used
165 as the numerator to calculate the proportion of RSV-associated hospitalisations among
166 respiratory and all-cause hospitalisations (data related to 2015) occurring in children under 5
167 years. The population denominator (roughly 25,900,000 children under 59 months of age in
168 EU28 in 2015) and other demographic indicators used for the analysis were obtained from
169 Eurostat [11]. Statistical analyses were conducted using Stata version 16 (Stata Corp, College
170 Station, TX).

171

172 **Results**

173 *Results of the literature review and Stage 1*

174 The literature search in MEDLINE and EMBASE produced 1,372 unique entries, and an
175 additional 33 articles were found by backward citation chaining or because they had been
176 included by Li and colleagues in the previous systematic review [2] (Figure 1). Of these, 1,304
177 were excluded based on title and abstract and 101 were read in full text: 99 were excluded for
178 not matching the inclusion criteria; the main reason for exclusion was not presenting national
179 RSV-associated hospitalisation estimates calculated by using regression methods. Two studies,

180 in particular, were excluded as they focused on different age groups [12-13] but they provided
181 useful estimates as they covered a country (England) that was included in Stage 1 (estimates
182 for England were already available) and were therefore comparable to the data reported by
183 Johannesen et al [7]. Finally, two studies [14-15] reporting RSV-associated hospitalisation
184 estimates for Spain from 1997 to 2011 and for France during 2010-2018 were included in the
185 review and their estimates were used as input data for the statistical modelling (Stage 2).
186 Both studies reported RSV-associated hospitalisation rates per 100,000 children in age groups
187 that were slightly different to those used by Johannesen et al.; we therefore only used data
188 related to the age groups that were consistent with the estimates produced by Johannesen et al.
189 [7] (12-35 months and 36-59 months for Spain and 0-2 months, 3-5 months, and 6-11 months
190 for France). Moreover, the estimates for France were not annual but based on the epidemic
191 periods only (October to March), so we recalculated the estimates for the whole year by
192 arbitrarily assuming little RSV activity during April-September (10% of the activity observed
193 from October to March [16]).
194 In total, data from 8 countries were used as Stage 1 inputs [(Denmark, England, Finland,
195 Norway, Netherlands, Scotland, France (age groups 0-2 months, 3-5 months, 6-11 months),
196 and Spain (age groups 12-35 months, 36-59 months)] (Table 1).

197

198 *Stage 2 estimates*

199 We included Stage 1 estimates from 8 countries in our analysis, roughly representing 40% of
200 the population of the EU and Norway [17]. The results produced by the four models were
201 consistent across the age groups, the highest rates being calculated with the multiple imputation
202 approach and the lowest rates being calculated with the nearest neighbour matching approach
203 (5% variation between the highest and lowest estimates of RSV hospitalisation rates in children

204 aged 0-2 months) (see Supplementary material). Here, we present the results for the average of
205 the four models.

206 We estimated the average number and average annual rate (per 1,000 population) of RSV-
207 associated hospitalisations by age group in different countries (Table 2 and Table 3). We
208 estimated that an average of 245,244 (95%CI 224,688-265,799) hospital admissions with
209 respiratory infection were associated with RSV in the 28 EU countries per year in children
210 under the age of 5, with most cases occurring among children aged less than 1 year (74.9%)
211 and those aged 1-2 years (20.7%) (Table 4). Infants aged less than 2 months represented the
212 most affected group (71.6 per 1,000 population; 95%CI: 66.6-76.6), with the rates declining as
213 the children got older: 38.9 per 1,000 in children aged 3-5 months, 17.6 (6-11 months), 5.0 (12-
214 35 months) and 1.0 (36-59 months). Overall, we estimated that an average of 10 children per
215 1,000 living in the European Union are hospitalized due to RSV annually (average rates in
216 children 0-59 months: 10.06, 9.90-10.21 per 1,000 population).

217 We also estimated country-specific RSV-associated respiratory hospitalisations for each of the
218 29 countries and rates per 1,000 children (Table 2 and Table 3). The countries which had the
219 highest absolute number of estimated hospitalisations were France (46,027 hospitalisations per
220 year in children under 5 years), the UK (39,296 hospitalisations), and Germany (34,719
221 hospitalisations).

222 The hospitalisation rates varied widely across the EU: in the first age group (0-2 months) they
223 ranged from 47.4 (95%CI: 37.6-57.3) per 1,000 population in the Netherlands to 98.3 (88.5-
224 108.1) in France. The Netherlands presented the lowest rates in almost all the other age groups:
225 19.9 (14.5-25.4) per 1,000 population in children aged 3-5 months, 8.5 (5.7-11.3) in children
226 aged 6-11 months, 1.9 (0.8-2.9) in children aged 12-35 months. The lowest rates for the age
227 group 36-59 months were estimated for Norway (0.5, 95%CI 0.3-0.7). In the age group 0-5

228 years (0-59 months), the rates ranged from 8.61 (8.31-8.92) in Norway to 10.58 (10.30-18.86)
229 in Spain.

230 Most RSV-associated hospitalisations occurred in children aged less than 1 year (74.9%
231 averaged, ranging from 65.4% in Denmark to 80.7% in Spain (Table 4)). The youngest group
232 (0-2 months) was the most affected, with percentages ranging from 27.5% in Denmark to
233 43.8% in the Netherlands. RSV-associated hospitalisations were less likely in children aged
234 from 3 to 4 years (36-59 months), with the percentage ranging from 3.3% in Finland to 8.4%
235 in the Netherlands.

236

237 *Comparison with total paediatric hospitalisations and respiratory paediatric hospitalisations*

238 We compared the country estimates to total national paediatric hospitalisations and respiratory
239 paediatric hospitalisations in the EU and Norway and found that RSV-associated
240 hospitalisations represented from 1.8% (95%CI: 1.5-2.1; Lithuania) to 9.9 (95%CI: 8.4-11.5;
241 Finland) of total hospitalisations in children younger than 5 years (Table 5) [11]. This
242 percentage was higher for paediatric respiratory hospitalisations, ranging from 6.8% in
243 Lithuania to 51.6% in Sweden, and these percentages are likely to be much higher during the
244 winter, especially during the weeks when RSV circulates.

245

246 **Discussion**

247 Understanding the burden of disease caused by RSV, and specifically the incidence of
248 hospitalisations and deaths, will help understand the impact of RSV prevention programs (new
249 monoclonal antibodies and vaccines [18-21]). Our study estimated that an average of roughly
250 250,000 respiratory hospitalisations in children younger than 5 years were associated with RSV
251 each year in the 28 EU countries included in the analysis, with 3 out of 4 hospitalisations
252 (ranging from 65.4% in Denmark to 80.7% Spain) occurring on average in children aged 0-11

253 months and 96% in those aged less than 0-23 months (ranging from 93.9% in Portugal to 97.7%
254 in Norway) (Table 4).

255 We applied four extrapolation methods to obtain these estimates and saw no large differences
256 across the outcomes: this was reassuring as it suggests that our results are not driven by the
257 choice of a specific model. Consistently with previous studies, our results show an increase in
258 RSV hospital admissions with a decrease in patient age, with infants under 1 year having the
259 highest burden of RSV hospitalisations (especially those aged 0-2 months of age) [22]. Demont
260 and colleagues reported a similar percentage (70%) of hospitalisations associated with RSV
261 occurred in children <1 year [4] compared to our estimate for France (79%) and the EU-28
262 (75%; Table 4). Glatman-Freedman et al. (Israel), Saravanos et al. (Australia) and Arriola et
263 al. (United States) have also found the highest age-specific hospitalisation rates in children
264 aged 0-2 months, with reductions in the other age groups [23-25]. This confirms how RSV
265 immunisation programmes targeting the first 6 months of life could be highly effective in
266 reducing most of the RSV hospitalisation burden [2].

267 Our estimates (and specifically the hospitalisation rates) varied strongly across the different
268 EU countries, with the Netherlands having the lowest rates in almost all age groups (Norway
269 has the lowest rates in the age group 3-4 years) and France having the highest rates, with the
270 highest relative difference observed in the age group 12-35 months (the estimated rate for
271 France was 5 times higher than the Netherlands). This finding is not entirely surprising as these
272 results reflect the Stage 1 data inputs that were entered into the Stage 2 modelling procedure,
273 where the Netherlands had the lowest [7] and France the highest rates [15]. Differences in the
274 outcome coding and in the study design (the French study was conducted during the winter
275 season, and we, therefore, needed to recalculate the estimates for a whole year) may explain
276 the higher rates reported in France. From a methodological perspective, these results highlight

277 the importance of having Stage 1 estimates that are calculated in a harmonized manner as the
278 Stage 2 extrapolations are sensitive to the Stage 1 inputs [26].

279 Whilst it is important to properly understand the real burden of disease associated with RSV in
280 Europe and to estimate the potential impact of prevention efforts, it is not easy to compare our
281 country-specific results with findings from the literature, considering the use of other methods
282 to calculate these rates and the paucity of published studies. The recent, large perspective study
283 by Wildenbeest and colleagues [27], conducted in 5 European countries, reported lower but
284 comparable hospitalisation rates (1.8% RSV-associated hospitalisation in the first year of life
285 in healthy term-born infants, 3.3% in children <3 months). The lower rates reported by
286 Wildenbeest and colleagues might be related to the exclusion of pre-term infants or those at
287 highest risk for severe illness [28] which were included in the studies used in our analysis [7,
288 14-15]. Sanchez-Luna and colleagues reported between 5,997 (2005) and 8,637 (2012) hospital
289 discharges for RSV bronchiolitis (ICD-9 code 466.11 as the principal diagnosis) in Spain in
290 children aged under 1 year during 2004-2012 [28]. Our estimated number of average
291 admissions per year for Spain in this age group was 14,446 (95%CI 12,228-16,662) and this
292 reflects our hospitalisation estimate not being restricted to bronchiolitis, but all respiratory
293 hospitalisations. Moreover, as reported for England by Green et al. [29], there is an observed
294 general increase in RSV-associated admissions over the years that may be due to changes in
295 healthcare policies (an increase in hospital bed availability or a change in the admission
296 threshold) and this may explain the higher number of hospitalisations estimated by our study
297 for Spain. Our study also shows how hospitalisations due to RSV in children under 5 years
298 represent one of the leading causes of EU infant hospitalisations (Table 5): based on our
299 estimates, up to 1 in 10 hospitalized children under 5 years of age may be associated to RSV,
300 and this number is larger (around 4 out of 10 children in Italy, Portugal, Denmark and Finland,
301 1 out of 2 in Sweden) if we only consider respiratory hospitalisations (Table 5). Accurate and

302 reliable patient-based data on hospitalisations for multiple pathogens in children under 5 years
303 and the related cause(s) of the hospitalisation will be fundamental in assessing whether RSV is
304 actually the leading cause of infant hospitalisations in Europe, as recently demonstrated for the
305 United States [30].

306 Our study has a number of limitations: first, our extrapolations would benefit from more
307 countries with RSV-associated estimates to populate the statistical models (e.g., additional
308 country estimates in southern and eastern Europe); moreover, estimates based on prospectively
309 collected data are needed to produce more reliable results (see Supplementary material). A
310 second limitation is that the estimates used for Stage 1 are regression-based and this holds
311 inherent uncertainties related to country-specific collection methods of laboratory data and ICD
312 codes for hospital admissions (ICD-10 for all countries included except the study conducted in
313 Spain, in which ICD-9-CM was used) [31]. Without uniform reporting systems and consistent
314 coding practices, it is hard to generalize results to other countries. Despite this, whilst
315 differences in coding can be profound when looking at a single code, they are reduced when
316 the modelling builds on a wider range of codes (e.g., all respiratory codes, as done by
317 Johannesen and colleagues [7]), as clinical practices and coding guidelines are less affected.
318 Another limitation is that our estimates are based on country-specific hospitalisation rates that
319 were calculated for different time periods (see Table 1), thus possibly influenced by differences
320 in RSV circulation (e.g. types) over the years. Our study found substantial variation in the
321 hospitalisation rates across Europe, but we did not explore these differences as this would
322 require more advanced analysis methods which would include factors such as the circulation
323 of other respiratory viruses (e.g., influenza and SARS-CoV-2), healthcare (indicators related
324 to access and quality of healthcare or differences in the clinical practice), climatic and
325 environmental factors [32-33]. We also used two sets of ten indicators to produce the
326 extrapolations (see Supplementary material): these sets were chosen based on the availability

327 of data in all included countries (e.g., Scotland and England for the UK) and are not always
328 specific to RSV. From a statistical perspective, this point is not likely to influence the estimates
329 (as the indicators only aim to capture variability across countries), but it would be more elegant
330 to develop indicator sets that are better aligned with RSV, as was done for influenza [9]. For
331 example, the inclusion of indoor and outdoor pollution, which was reported by Nenna and
332 colleagues as a risk factor for acute bronchiolitis in infants aged less than 3 years old [34], or
333 the rates of premature birth, average maternal age, and delayed infant vaccinations, reported
334 by Hardelid and co-authors as risk factors associated with increased RSV hospitalisations,
335 could be considered [35]). Finally, our extrapolations are based on a period in which COVID-
336 19 was not present: it would be preferable to have more recent estimates to understand the
337 impact of the COVID-19 pandemic on RSV circulation [36] and its burden in terms of
338 infections, hospitalisations, and deaths.

339 Despite these limitations, our study is, to our knowledge, the first attempt to estimate the RSV
340 hospitalisation burden in children under the age of 5 years across Europe, and in EU countries
341 for which no estimates have been produced so far. These estimates should help optimize public
342 health responses (e.g., the allocation of more resources to pediatric hospitals during the winter
343 season) and support planning for future immunisation programs [37]. Moreover, they represent
344 a benchmark to understand to understand changes in the RSV burden after the COVID-19
345 pandemic and in the future following the introduction of RSV immunisation programs in
346 Europe.

347

348 Study group members

349 The RESCEU investigators are as follows:

350 Harish NAIR (University of Edinburgh), Harry CAMPBELL (University of Edinburgh),

351 Philippe Beutels (Universiteit Antwerpen), Louis Bont (University Medical Center Utrecht),

352 Andrew Pollard (University of Oxford), Peter Openshaw (Imperial College London), Federico
353 Martinon-Torres (Servicio Galego de Saude), Terho Heikkinen (University of Turku and Turku
354 University Hospital), Adam Meijer (National Institute for Public Health and the Environment),
355 Thea K. Fischer (Statens Serum Institut), Maarten van den Berge (University of Groningen),
356 Carlo Giaquinto (PENTA Foundation), Michael Abram (AstraZeneca), Kena Swanson
357 (Pfizer), Bishoy Rizkalla (GlaxoSmithKline), Charlotte Vernhes (Sanofi Pasteur), Scott
358 Gallichan (Sanofi Pasteur), Jeroen Aerssens (Janssen), Veena Kumar (Novavax), Eva Molero
359 (Team-It Research)

360

361 Financial support

362 This work is part of RESCEU. RESCEU has received funding from the Innovative Medicines
363 Initiative 2 Joint Undertaking under grant agreement No 116019. This Joint Undertaking
364 receives support from the European Union's Horizon 2020 research and innovation programme
365 and EFPIA. This publication only reflects the author's view, and the JU is not responsible for
366 any use that may be made of the information it contains herein.

367

368 Disclaimer

369 Data from the Norwegian Patient Registry have been used in this publication. The
370 interpretation and reporting of these data are the sole responsibility of the authors, and no
371 endorsement by the Norwegian Patient Registry is intended nor should be inferred. This work
372 reflects only the author's views and opinions. The EC is not responsible for any use that may
373 be made of the information it contains.

374

375 Potential conflicts of interest

376 HC reports grants, personal fees, and nonfinancial support from World Health Organization.
377 Grants and personal fees from Sanofi Pasteur. Grants from Bill and Melinda Gates Foundation.
378 All payments were made via the University of Edinburgh. HC is a shareholder in the Journal
379 of Global Health Ltd. JP declares that Nivel has received unrestricted research grants regarding
380 the epidemiology of RSV from Sanofi Pasteur and IMI in the past 12 months.

381 Table 1. Description of the data sources that provided Stage 1 estimates

Author, year	Country	Period of observation	Age groups	Age groups whose estimates were used as inputs	Outcome coding
Johannesen, 2022 [7]	Denmark	2010-2017	0-2m, 3-5m, 6-11m, 12-35m, 36-59m	0-2m, 3-5m, 6-11m, 12-35m, 36-59m	ICD-10; J00, J02-06 acute upper respiratory tract infection (URTI); J09-18 Pneumonia & influenza; J20-21, J40 Bronchiolitis and bronchitis; J22 Unspecified LRTI
Johannesen, 2022 [7]	England	2007-2017	0-2m, 3-5m, 6-11m, 12-35m, 36-59m	0-2m, 3-5m, 6-11m, 12-35m, 36-59m	ICD-10; J00, J02-06 acute upper respiratory tract infection (URTI); J09-18 Pneumonia & influenza; J20-21, J40 Bronchiolitis and bronchitis; J22 Unspecified LRTI
Johannesen, 2022 [7]	Finland	2006-2016	0-2m, 3-5m, 6-11m, 12-35m, 36-59m	0-2m, 3-5m, 6-11m, 12-35m, 36-59m	ICD-10; J00, J02-06 acute upper respiratory tract infection (URTI); J09-18 Pneumonia & influenza; J20-21, J40 Bronchiolitis and bronchitis; J22 Unspecified LRTI
Johannesen, 2022 [7]	Netherlands	2013-2017	0-2m, 3-5m, 6-11m, 12-35m, 36-59m	0-2m, 3-5m, 6-11m, 12-35m, 36-59m	ICD-10; J00, J02-06 acute upper respiratory tract infection (URTI); J09-18 Pneumonia & influenza; J20-21, J40 Bronchiolitis and bronchitis; J22 Unspecified LRTI
Johannesen, 2022 [7]	Norway	2008-2017	0-2m, 3-5m, 6-11m, 12-35m, 36-59m	0-2m, 3-5m, 6-11m, 12-35m, 36-59m	ICD-10; J00, J02-06 acute upper respiratory tract infection (URTI); J09-18 Pneumonia & influenza; J20-21, J40 Bronchiolitis and bronchitis; J22 Unspecified LRTI
Johannesen, 2022 [7]	Scotland	2010-2016	0-2m, 3-5m, 6-11m, 12-35m, 36-59m	0-2m, 3-5m, 6-11m, 12-35m, 36-59m	ICD-10; J00, J02-06 acute upper respiratory tract infection (URTI); J09-18 Pneumonia & influenza; J20-21, J40 Bronchiolitis and bronchitis; J22 Unspecified LRTI
Demont, 2020 [15]	France	2010-2018	0-2m, 3-5m, 6-11m, 12-23m, 24-59m	0-2m, 3-5m, 6-11m	ICD-10; J121, J205, J210, J219
Gil-Prieto, 2015 [14]	Spain	1997-2011	0y, 1y, 2y, 3y, 4y, <5y, <2y	2y, 3y, 4y	ICD-9-CM; 466, acute bronchitis and bronchiolitis; 480.1, pneumonia due to RSV; 079.6, RSV infection

382 Table 2: Average RSV-associated hospitalisation rates per 1,000 population per age group per year

Country	0-2 months (95%CI) ^a	3-5 months (95%CI) ^a	6-11 months (95%CI) ^a	12-35 months (95%CI) ^b	36-59 months (95%CI) ^b
EU28 ^c	71.6 (66.6-76.6)	38.9 (36-41.9)	17.6 (16.1-19.1)	5 (4.4-5.5)	1 (0.9-1.1)
Austria	65 (55.2-74.8)	33.1 (27.7-38.5)	13.5 (10.7-16.4)	4.5 (3.5-5.5)	0.9 (0.7-1.1)
Belgium	68.6 (58.8-78.4)	36.3 (30.9-41.7)	15.9 (13.1-18.7)	4.8 (3.8-5.9)	1.2 (0.9-1.4)
Bulgaria	81.8 (72-91.6)	48.9 (43.5-54.3)	21.2 (18.4-24)	5.5 (4.5-6.6)	1 (0.8-1.2)
Croatia	79.4 (69.7-89.2)	42.6 (37.2-48)	19 (16.2-21.8)	4.8 (3.8-5.8)	0.9 (0.7-1.1)
Cyprus	78.4 (68.6-88.2)	41.3 (35.9-46.7)	16.7 (13.9-19.5)	5.5 (4.5-6.5)	0.9 (0.7-1.1)
Czech Republic	73.9 (64.1-83.7)	41 (35.6-46.4)	18.4 (15.6-21.2)	5.7 (4.6-6.7)	1.1 (0.9-1.3)
Denmark	59.2 (49.3-69)	40.7 (35.3-46.2)	20.4 (17.5-23.2)	7.5 (6.4-8.5)	1.6 (1.4-1.8)
Estonia	69.8 (60-79.7)	37.3 (31.8-42.7)	17.2 (14.4-20.1)	5.1 (4-6.1)	1 (0.8-1.2)
Finland	77.8 (67.9-87.7)	43.2 (37.7-48.6)	16.6 (13.8-19.4)	5.2 (4.2-6.3)	0.8 (0.6-1)
France	98.3 (88.5-108.1)	48.8 (43.4-54.2)	26 (23.2-28.8)	5 (4-6.1)	1.1 (0.9-1.3)
Germany	72.5 (62.7-82.2)	38.6 (33.2-44)	17.5 (14.6-20.3)	5.2 (4.2-6.3)	1 (0.8-1.2)
Greece	82.6 (72.8-92.4)	44.3 (38.9-49.7)	19.1 (16.3-21.9)	4.5 (3.4-5.5)	0.9 (0.7-1.1)
Hungary	75.3 (65.5-85.1)	44.7 (39.3-50.1)	19.8 (16.9-22.6)	5.4 (4.4-6.4)	1.1 (0.9-1.3)
Ireland	70.1 (60.3-79.9)	47 (41.6-52.4)	22.6 (19.8-25.4)	7.1 (6-8.1)	1.3 (1-1.5)
Italy	80.9 (71.1-90.7)	41.7 (36.3-47.1)	18.1 (15.3-20.9)	4.3 (3.2-5.3)	0.9 (0.7-1.1)

Latvia	75 (65.2-84.8)	41.3 (35.9-46.7)	18.4 (15.6-21.2)	4.6 (3.6-5.7)	1.1 (0.8-1.3)
Lithuania	73.6 (63.8-83.4)	38.5 (33.1-43.9)	17 (14.2-19.8)	4 (3-5)	0.9 (0.7-1.1)
Luxembourg	63.5 (53.7-73.3)	32.6 (27.2-38)	13.1 (10.3-15.9)	5 (4-6.1)	0.9 (0.7-1.1)
Malta	64.8 (54.8-74.7)	35.2 (29.7-40.7)	17.9 (15-20.7)	5.4 (4.4-6.5)	1.3 (1.1-1.5)
Netherlands	47.4 (37.6-57.3)	19.9 (14.5-25.4)	8.5 (5.7-11.3)	1.9 (0.8-2.9)	1.1 (0.9-1.3)
Norway	54.6 (44.5-64.7)	34.8 (29.3-40.3)	15.4 (12.5-18.2)	6.6 (5.6-7.7)	0.5 (0.3-0.7)
Poland	71.4 (61.6-81.2)	36.5 (31.1-41.9)	16.2 (13.4-19.1)	4.6 (3.5-5.6)	0.9 (0.7-1.1)
Portugal	70.2 (60.4-80)	31.7 (26.3-37.1)	15.2 (12.4-18)	4.5 (3.4-5.5)	1.2 (0.9-1.4)
Romania	68.8 (59-78.6)	37.7 (32.3-43.1)	19.4 (16.6-22.2)	4.1 (3.1-5.2)	1 (0.8-1.2)
Slovakia	74.6 (64.8-84.3)	42 (36.6-47.4)	18.8 (16-21.6)	4.7 (3.7-5.8)	0.8 (0.6-1)
Slovenia	75.4 (65.6-85.2)	42.6 (37.2-48)	17.6 (14.8-20.4)	5.2 (4.2-6.2)	1.1 (0.9-1.3)
Spain	69.4 (59.6-79.2)	32.6 (27.2-38)	16.8 (14-19.6)	3 (2-4.1)	0.8 (0.6-1)
Sweden	63 (53.1-72.8)	35.5 (30.1-41)	16.9 (14.1-19.7)	5.3 (4.3-6.3)	1.2 (1-1.4)
United Kingdom	63.4 (47.8-79.1)	38.9 (29.7-48.1)	18.9 (14.2-23.6)	6.1 (4.4-7.9)	1.3 (1-1.6)

383 ^a RSV-associated hospitalisation rates in these three age groups for the 29 countries are estimated by also including data from France reported by Demont and

384 colleagues [15]

385 ^b RSV-associated hospitalisation rates in these two age groups for the 29 countries are estimated by also including data from Spain reported by Gil-Prieto and colleagues

386 [14]

387 ^c Includes the UK and excludes Norway

388 Table 3: Average RSV-associated hospitalisations per age group per year

Country	0-2 months (95%CI) ^a	3-5 months (95%CI) ^a	6-11 months (95%CI) ^a	12-35 months (95%CI) ^b	36-59 months (95%CI) ^b
EU28 ^c	90,200 (83,923-96,476)	49,052 (45,328-52,776)	44,369 (40,529-48,208)	50,852 (45,249-56,456)	10,771 (9,659-11,883)
Austria	1,308 (1,111-1,505)	667 (558-775)	545 (432-658)	732 (563-902)	147 (112-182)
Belgium	2,141 (1,836-2,446)	1,133 (965-1,302)	992 (816-1,167)	1,235 (973-1,497)	306 (250-362)
Bulgaria	1,374 (1,210-1,539)	822 (732-913)	714 (620-808)	733 (596-869)	141 (112-171)
Croatia	783 (687-880)	420 (366-473)	375 (320-431)	391 (306-477)	77 (59-95)
Cyprus	181 (159-204)	95 (83-108)	77 (64-90)	106 (86-126)	18 (13-22)
Czech Republic	2,031 (1,762-2,300)	1,128 (979-1,276)	1,012 (858-1,167)	1,237 (1,012-1,462)	258 (209-308)
Denmark	846 (704-986)	582 (504-660)	582 (500-662)	864 (744-985)	199 (172-225)
Estonia	238 (205-271)	127 (108-146)	118 (98-137)	141 (112-170)	32 (25-38)
Finland	1,122 (980-1,264)	622 (544-701)	479 (398-561)	625 (501-750)	97 (71-124)
France	18,145 (16,336-19,952)	9,018 (8,021-10,015)	9,587 (8,548-10,626)	7,573 (5,998-9,148)	1,704 (1,368-2,040)
Germany	12,977 (11,223-14,731)	6,906 (5,939-7,874)	6,252 (5,244-7,260)	7,250 (5,802-8,699)	1,334 (1,039-1,629)
Greece	1,895 (1,670-2,119)	1,015 (891-1,139)	875 (746-1,003)	862 (661-1,063)	193 (147-239)
Hungary	1,748 (1,521-1,975)	1,038 (913-1,163)	917 (787-1,048)	976 (788-1,164)	199 (161-237)
Ireland	1,139 (980-1,298)	764 (676-851)	735 (643-826)	950 (810-1,091)	176 (146-206)
Italy	10,111 (8,888-11,334)	5,213 (4,538-5,888)	4,534 (3,832-5,236)	4,475 (3,387-5,563)	1,021 (787-1,256)

Latvia	407 (353-459)	224 (195-253)	200 (169-230)	190 (148-232)	40 (32-48)
Lithuania	559 (485-633)	292 (251-333)	258 (215-300)	241 (179-304)	54 (42-67)
Luxembourg	96 (82-111)	49 (41-58)	40 (31-49)	64 (51-77)	12 (9-15)
Malta	69 (59-80)	38 (32-44)	38 (32-44)	47 (38-57)	11 (9-13)
Netherlands	2,071 (1,641-2,502)	870 (633-1,108)	741 (494-988)	651 (292-1,011)	398 (319-475)
Norway	811 (661-961)	517 (435-599)	456 (370-542)	812 (682-941)	61 (34-89)
Poland	6,542 (5,646-7,439)	3,346 (2,852-3,842)	2,979 (2,464-3,494)	3,459 (2,669-4,249)	730 (557-903)
Portugal	1,444 (1,243-1,645)	651 (540-762)	627 (511-742)	769 (590-949)	226 (185-268)
Romania	3,300 (2,830-3,769)	1,807 (1,548-2,066)	1,860 (1,590-2,129)	1,540 (1,150-1,929)	389 (305-472)
Slovakia	1,035 (900-1,170)	583 (509-658)	523 (445-600)	531 (414-648)	98 (72-123)
Slovenia	399 (347-451)	225 (197-254)	186 (156-216)	225 (180-270)	48 (38-57)
Spain	7,399 (6,356-8,442)	3,473 (2,897-4,048)	3,574 (2,975-4,172)	2,670 (1,762-3,578)	788 (585-992)
Sweden	1,824 (1,538-2,110)	1,030 (872-1,187)	980 (816-1,144)	1,229 (987-1,471)	288 (237-339)
United Kingdom	12,333 (9,291-15,375)	7,565 (5,778-9,351)	7,352 (5,515-9,188)	9,890 (7,128-12,652)	2,156 (1,614-2,698)

389 ^a RSV-associated hospitalisation in these three age groups are estimated by also including data from France reported by Demont and colleagues [15]

390 ^b RSV-associated hospitalisation in these two age groups are estimated by also including data from Spain reported by Gil-Prieto and colleagues [14]

391 ^c Includes the UK and excludes Norway

392 Table 4: Ratio of RSV-associated hospitalisation occurring in children aged less than 1 year, from 1 to 2 years and from 3 to 4 years (100% is
 393 represented by all RSV-associated hospitalisation occurring in children under 5 years).

Country	0-2 months ^a - %	3-5 months ^a - %	6-11 months ^a - %	0-11 months ^{a,b} - %	12-35 months ^c - %	36-59 months ^c - %
EU28 ^d	36.8%	20.0%	18.1%	74.9	20.7	4.4
Austria	38.5%	19.6%	16.0%	74.1	21.6	4.3
Belgium	36.9%	19.5%	17.1%	73.4	21.3	5.3
Bulgaria	36.3%	21.7%	18.9%	76.9	19.4	3.7
Croatia	38.3%	20.5%	18.3%	77.1	19.1	3.8
Cyprus	37.9%	19.9%	16.1%	74.0	22.2	3.8
Czech Republic	35.8%	19.9%	17.9%	73.6	21.8	4.6
Denmark	27.5%	18.9%	18.9%	65.4	28.1	6.5
Estonia	36.3%	19.4%	18.0%	73.6	21.5	4.9
Finland	38.1%	21.1%	16.3%	75.5	21.2	3.3
France	39.4%	19.6%	20.8%	79.8	16.5	3.7
Germany	37.4%	19.9%	18.0%	75.3	20.9	3.8
Greece	39.2%	21.0%	18.1%	78.2	17.8	4.0
Hungary	35.8%	21.3%	18.8%	75.9	20.0	4.1
Ireland	30.3%	20.3%	19.5%	70.1	25.2	4.7

Italy	39.9%	20.6%	17.9%	78.3	17.7	4.0
Latvia	38.4%	21.1%	18.9%	78.3	17.9	3.8
Lithuania	39.8%	20.8%	18.4%	79.0	17.2	3.8
Luxembourg	36.8%	18.8%	15.3%	70.9	24.5	4.6
Malta	34.0%	18.7%	18.7%	71.4	23.2	5.4
Netherlands	43.8%	18.4%	15.7%	77.8	13.8	8.4
Norway	30.5%	19.5%	17.2%	67.1	30.6	2.3
Poland	38.4%	19.6%	17.5%	75.4	20.3	4.3
Portugal	38.8%	17.5%	16.9%	73.2	20.7	6.1
Romania	37.1%	20.3%	20.9%	78.3	17.3	4.4
Slovakia	37.4%	21.0%	18.9%	77.3	19.2	3.5
Slovenia	36.8%	20.8%	17.2%	74.8	20.8	4.4
Spain	41.3%	19.4%	20.0%	80.7	14.9	4.4
Sweden	34.1%	19.2%	18.3%	71.6	23.0	5.4
United Kingdom	31.4%	19.3%	18.7%	69.3	25.2	5.5

394 ^a RSV-associated hospitalisations in this age group are estimated by also including data from France reported by Demont and colleagues [15]

395 ^b Calculated as a total of the previous three age groups (0-2 months, 3-5 months, 6-11 months)

396 ^c RSV-associated hospitalisations in these two age groups are estimated by also including data from Spain reported by Gil-Prieto and colleagues [14]

397 ^d Includes the UK and excludes Norway

398 Table 5: Hospitalizations in children under 5 years (all causes and respiratory causes) in EU28 countries and Norway, and % of all

399 hospitalisations and all respiratory hospitalisations that were due to RSV.

Country	Hospitalizations in children under 5 years, all causes ^a	Hospitalizations in children under 5 years, respiratory causes ^a	RSV-associated hospitalisations in children under 5 years ^b	% of all hospitalisations in children under 5 years due to RSV	% of all respiratory hospitalisations in children under 5 years due to RSV
Austria	na	16,305	3,399 (2,776-4,022)		20.8 (17.0-24.7)
Belgium	na	na	5,807 (4,840-6,774)		
Bulgaria	na	na	3,784 (3,270-4,300)		
Croatia	62,972	8,060	2,046 (1,738-2,356)	3.2 (2.8-3.7)	25.4 (21.6-29.2)
Cyprus	6,839	1,568	477 (405-550)	7.0 (5.9-8.0)	30.4 (25.8-35.1)
Czech Republic	196,900	26,813	5,666 (4,820-6,513)	2.9 (2.4-3.3)	21.1 (18.0-24.3)
Denmark	47,695	7,672	3,073 (2,624-3,518)	6.4 (5.5-7.4)	40.1 (34.2-45.9)
Estonia	na	na	656 (548-762)		
Finland	29,637	6,854	2,945 (2,494-3,400)	9.9 (8.4-11.5)	43.0 (36.4-49.6)
France	1,229,788	127,538	46,027 (40,271-51,781)	3.7 (3.3-4.2)	36.1 (31.6-40.6)
Germany	1,253,873	162,515	34,719 (29,247-40,193)	2.8 (2.3-3.2)	21.4 (18.0-24.7)
Greece	na	na	4,840 (4,115-5,563)		
Hungary	175,698	29,555	4,878 (4,170-5,587)	2.8 (2.4-3.2)	16.5 (14.1-18.9)

Ireland	53,504	11,637	3,764 (3,255-4,272)	7.0 (6.1-8.0)	32.3 (28.0-36.7)
Italy	731,993	62,922	25,354 (21,432-29,277)	3.5 (2.9-4.0)	40.3 (34.1-46.5)
Latvia	na	9,608	1,061 (897-1,222)		11.0 (9.3-12.7)
Lithuania	78,166	20,663	1,404 (1,172-1,637)	1.8 (1.5-2.1)	6.8 (5.7-7.9)
Luxembourg	na	777	261 (214-310)		33.6 (27.5-39.9)
Malta	7,030	642	203 (170-238)	2.9 (2.4-3.4)	31.6 (26.5-37.1)
Netherlands	na	18,201	4,731 (3,379-6,084)		26.0 (18.6-33.4)
Norway	84,850	7,251	2,657 (2,182-3,132)	3.1 (2.6-3.7)	36.6 (30.1-43.2)
Poland	664,693	120,409	17,056 (14,188-19,927)	2.6 (2.1-3.0)	14.2 (11.8-16.5)
Portugal	98,167	8,069	3,717 (3,069-4,366)	3.8 (3.1-4.4)	46.1 (38.0-54.1)
Romania	424,339	123,377	8,896 (7,423-10,365)	2.1 (1.7-2.4)	7.2 (6.0-8.4)
Slovakia	113,651	19,071	2,770 (2,340-3,199)	2.4 (2.1-2.8)	14.5 (12.3-16.8)
Slovenia	46,511	7,346	1,083 (918-1,248)	2.3 (2.0-2.7)	14.7 (12.5-17.0)
Spain	na	58,598	17,904 (14,575-21,232)		30.6 (24.9-36.2)
Sweden	na	10,362	5,351 (4,450-6,251)		51.6 (42.9-60.3)
United Kingdom	979,392	116,819	39,296 (29,326-49,264)	4.0 (3.0-5.0)	33.6 (25.1-42.2)

400 na: not available

401 ^aData are related to 2015 [11]

402 ^bEstimates calculated in the present manuscript.

403 **References**

- 404 1. Shi T, McAllister DA, O'Brien KL, et al. Global, regional, and national disease burden
405 estimates of acute lower respiratory infections due to respiratory syncytial virus in
406 young children in 2015: a systematic review and modelling study. *Lancet* 2017; 390:
407 946–958.
- 408 2. Li Y, Wang X, Blau DM, et al. Global, regional, and national disease burden estimates
409 of acute lower respiratory infections due to respiratory syncytial virus in children
410 younger than 5 years in 2019: a systematic analysis. *Lancet* 2022; 399: 2047–2064.
- 411 3. Reeves RM, van Wijhe M, Tong S, et al. Respiratory Syncytial Virus-Associated
412 Hospital Admissions in Children Younger Than 5 Years in 7 European Countries Using
413 Routinely Collected Datasets. *J Infect Dis* 2020; 222: S599–S605.
- 414 4. Demont C, Petrica N, Bardoulat I, et al. Economic and disease burden of RSV-
415 associated hospitalisations in young children in France, from 2010 through 2018. *BMC*
416 *Infect Dis* 2021; 21: 730.
- 417 5. Lee N, Walsh EE, Sander I, et al. Delayed Diagnosis of Respiratory Syncytial Virus
418 Infections in Hospitalized Adults: Individual Patient Data, Record Review Analysis and
419 Physician Survey in the United States. *J Infect Dis* 2019; 220: 969–979.
- 420 6. Modjarrad K, Giersing B, Kaslow DC, et al. WHO consultation on Respiratory
421 Syncytial Virus Vaccine Development Report from a World Health Organization
422 Meeting held on 23-24 March 2015. *Vaccine* 2016. p. 190–197.
- 423 7. Johannesen CK, van Wijhe M, Tong S, et al. Age-Specific Estimates of Respiratory
424 Syncytial Virus-Associated Hospitalizations in 6 European Countries: A Time Series
425 Analysis. *J Infect Dis* 2022; 226: S29–S37.
- 426 8. Page MJ, McKenzie JE, Bossuyt PM, et al. The PRISMA 2020 statement: an updated
427 guideline for reporting systematic reviews. *BMJ* 2021; 372: n71.

- 428 9. Simonsen L, Spreeuwenberg P, Lustig R, et al. Global mortality estimates for the 2009
429 Influenza Pandemic from the GLaMOR project: a modeling study. *PLoS Med* 2013;
430 10: e1001558.
- 431 10. Paget J, Spreeuwenberg P, Charu V, et al. Global mortality associated with seasonal
432 influenza epidemics: New burden estimates and predictors from the GLaMOR Project.
433 *J Glob Health* 2019; 9: 20421.
- 434 11. Eurostat. Hospital discharges and length of stay statistics. Available at:
435 [https://ec.europa.eu/eurostat/statistics-](https://ec.europa.eu/eurostat/statistics-explained/index.php?title=Hospital_discharges_and_length_of_stay_statistics&oldid=561104#Hospital_discharges_by_sex_and_age)
436 [explained/index.php?title=Hospital_discharges_and_length_of_stay_statistics&oldid=](https://ec.europa.eu/eurostat/statistics-explained/index.php?title=Hospital_discharges_and_length_of_stay_statistics&oldid=561104#Hospital_discharges_by_sex_and_age)
437 [561104#Hospital_discharges_by_sex_and_age](https://ec.europa.eu/eurostat/statistics-explained/index.php?title=Hospital_discharges_and_length_of_stay_statistics&oldid=561104#Hospital_discharges_by_sex_and_age) [last accessed 10 July 2022]
- 438 12. Reeves RM, Hardelid P, Gilbert R, et al. Estimating the burden of respiratory syncytial
439 virus (RSV) on respiratory hospital admissions in children less than five years of age
440 in England, 2007-2012. *Influenza Other Respir Viruses* 2017; 11: 122–129.
- 441 13. Cromer D, van Hoek AJ, Newall AT, et al. Burden of paediatric respiratory syncytial
442 virus disease and potential effect of different immunisation strategies: a modelling and
443 cost-effectiveness analysis for England. *Lancet Public Health* 2017; 2: e367–e374.
- 444 14. Gil-Prieto R, Gonzalez-Escalada A, Marín-García P, et al. Respiratory Syncytial Virus
445 Bronchiolitis in Children up to 5 Years of Age in Spain: Epidemiology and
446 Comorbidities: An Observational Study. *Medicine* 2015; 94: e831.
- 447 15. Demont C, Bizouard G, Watier L, et al. Excess hospitalisations associated with RSV
448 among children under 5 years old in France from 2010 to 2018. *ESCAIDE Abstract*
449 *Book*. 2020. 24-27 November. Available at: [https://www.escaide.eu/en/general-](https://www.escaide.eu/en/general-information/abstract-books)
450 [information/abstract-books](https://www.escaide.eu/en/general-information/abstract-books) [Last accessed 30 June 2022].

- 451 16. Li Y, Wang X, Broberg EK, et al. Seasonality of respiratory syncytial virus and its
452 association with meteorological factors in 13 European countries, week 40 2010 to
453 week 39 2019. *Euro Surveill* 2022; 27.
- 454 17. Eurostat. Demography, population stock, and balance. Available at:
455 [https://ec.europa.eu/eurostat/web/population-demography/demography-population-
456 stock-balance/database](https://ec.europa.eu/eurostat/web/population-demography/demography-population-
456 stock-balance/database) [last accessed 10 July 2022]
- 457 18. Hammitt LL, Dagan R, Yuan Y, et al. Nirsevimab for Prevention of RSV in Healthy
458 Late-Preterm and Term Infants. *N Engl J Med* 2022; 386: 837–846.
- 459 19. Karron RA. Preventing respiratory syncytial virus (RSV) disease in children. *Science*
460 2021; 372: 686–687.
- 461 20. Mazur NI, Terstappen J, Baral R, et al. Respiratory syncytial virus prevention within
462 reach: the vaccine and monoclonal antibody landscape. *Lancet Infect Dis* 2023; 23: e2–
463 e21.
- 464 21. Teirlinck AC, Broberg EK, Stuwitz Berg A, et al. Recommendations for respiratory
465 syncytial virus surveillance at the national level. *Eur Respir J* 2021; 58.
- 466 22. Bont L, Checchia PA, Fauroux B, et al. Defining the Epidemiology and Burden of
467 Severe Respiratory Syncytial Virus Infection Among Infants and Children in Western
468 Countries. *Infect Dis Ther* 2016; 5: 271–298.
- 469 23. Glatman-Freedman A, Kaufman Z, Applbaum Y, et al. Respiratory Syncytial Virus
470 hospitalisation burden: a nation-wide population-based analysis, 2000-2017. *J Infect*
471 2020; 81: 297–303.
- 472 24. Saravanos GL, Sheel M, Homaira N, et al. Respiratory syncytial virus-associated
473 hospitalisations in Australia, 2006-2015. *Med J Aust* 2019; 210: 447–453.

- 474 25. Arriola CS, Kim L, Langley G, et al. Estimated Burden of Community-Onset
475 Respiratory Syncytial Virus-Associated Hospitalizations Among Children Aged <2
476 Years in the United States, 2014-15. *J Pediatric Infect Dis Soc* 2020; 9: 587–595.
- 477 26. Paget J, Danielle Iuliano A, Taylor RJ, et al. Estimates of mortality associated with
478 seasonal influenza for the European Union from the GLaMOR project. *Vaccine* 2022;
479 40: 1361–1369.
- 480 27. Sanchez-Luna M, Elola FJ, Fernandez-Perez C, et al. Trends in respiratory syncytial
481 virus bronchiolitis hospitalisations in children less than 1 year: 2004-2012. *Curr Med
482 Res Opin* 2016; 32: 693–698.
- 483 28. American Lung Association. Learn about respiratory syncytial virus (RSV). 2021.
484 Available at: [https://www.lung.org/lung-health-diseases/lung-disease-
485 lookup/rsv/learn-about-rsv](https://www.lung.org/lung-health-diseases/lung-disease-lookup/rsv/learn-about-rsv). Last accessed [20 Dec 2022].
- 486 29. Wildenbeest JG, Billard M-N, Zuurbier RP, et al. The burden of respiratory syncytial
487 virus in healthy term-born infants in Europe: a prospective birth cohort study. *Lancet
488 Respir Med* 2022.
- 489 30. Green CA, Yeates D, Goldacre A, et al. Admission to hospital for bronchiolitis in
490 England: trends over five decades, geographical variation and association with perinatal
491 characteristics and subsequent asthma. *Arch Dis Child* 2016; 101: 140–146.
- 492 31. Suh M, Movva N, Jiang X, et al. Respiratory Syncytial Virus Is the Leading Cause of
493 United States Infant Hospitalizations, 2009-2019: A Study of the National
494 (Nationwide) Inpatient Sample. *J Infect Dis* 2022; 226: S154–S163.
- 495 32. Simoes EAF. Environmental and demographic risk factors for respiratory syncytial
496 virus lower respiratory tract disease. *J Pediatr* 2003; 143: S118–26.
- 497 33. Fitzpatrick T, McNally JD, Stukel TA, et al. Family and Child Risk Factors for Early-
498 Life RSV Illness. *Pediatrics* 2021; 147.

- 499 34. Nenna R, Cutrera R, Frassanito A, et al. Modifiable risk factors associated with
500 bronchiolitis. *Ther Adv Respir Dis* 2017; 11: 393–401.
- 501 35. Hardelid P, Verfuerden M, McMenamin J, et al. The contribution of child, family and
502 health service factors to respiratory syncytial virus (RSV) hospital admissions in the
503 first 3 years of life: birth cohort study in Scotland, 2009 to 2015. *Euro Surveill* 2019;
504 24.
- 505 36. van Summeren J, Meijer A, Aspelund G, et al. Low levels of respiratory syncytial virus
506 activity in Europe during the 2020/21 season: what can we expect in the coming
507 summer and autumn/winter? *Euro Surveill* 2021; 26.
- 508 37. Sande CJ. Implementation strategies for passive respiratory syncytial virus
509 immunisation. *Lancet Infect Dis* 2021; 21: 1200–120
510

Figure 1: Systematic review flow diagram




Figure 2: RSV Hospitalization rates per 1,000 population in different age groups

